Form 4: Bio-Techne Director Rupert Vessey Reports Acquisition and Disposal of Common Stock
SEC Form 4 Filing
Director Rupert Vessey reports acquiring and disposing of Bio-Techne Corp common stock and acquiring derivative securities.
Summary
- On October 24, 2024, Rupert Vessey, a director of Bio-Techne Corp, reported a transaction involving the company's common stock.
- Vessey acquired 1,462 shares of common stock.
- Vessey disposed of 9,347 shares of common stock.
- Following these transactions, Vessey beneficially owns 9,347 shares of common stock.
- Vessey also acquired 3,511 stock options with an exercise price of $68.37, exercisable starting October 24, 2034.
- Vessey directly owns multiple tranches of stock options with varying exercise prices and expiration dates.
Sentiment
Score: 5
Explanation: Neutral sentiment as the document primarily reports transactions without expressing opinions or providing detailed context. The disposal of shares is balanced by the acquisition of new stock options.
Positives
- The acquisition of stock options demonstrates the director's continued investment in the company's future.
Negatives
- The disposal of 9,347 shares could be interpreted negatively, although the reason for the disposal is not disclosed.
Risks
- The document does not explicitly state any risks.
- However, any significant disposal of shares by a director could potentially signal concerns about the company's prospects.
Future Outlook
The document does not contain explicit forward-looking statements, but the vesting of the new stock options is contingent on the earlier of one year from the grant date or the date of Bio-Techne's 2025 annual meeting of shareholders.
Industry Context
Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company insiders, which can be informative for investors.
Comparison to Industry Standards
- Comparing Vessey's transactions to those of other directors in similar biotechnology companies would provide a benchmark for assessing the significance of these changes in ownership.
- Analyzing the ratio of stock options to directly held shares against industry averages could offer insights into the company's executive compensation strategy.
Stakeholder Impact
- The transactions could have a minor impact on shareholders' perception of the company, depending on how they interpret the director's actions.
- The granting of stock options could motivate the director to work towards the company's success, benefiting stakeholders.
Key Dates
| Date | Description |
|---|---|
| 10/24/2019 | Date of stock options grant with exercise price $52.32, expiring 10/25/2029. |
| 10/24/2020 | Date of stock options grant with exercise price $50.41, expiring 10/24/2029. |
| 10/28/2021 | Date of stock options grant with exercise price $63.92, expiring 10/29/2030. |
| 10/27/2022 | Date of stock options grant with exercise price $128.81, expiring 10/28/2031. |
| 10/26/2023 | Date of stock options grant with exercise price $73.94, expiring 10/27/2032. |
| 10/24/2024 | Date of transaction: acquisition and disposal of common stock and acquisition of stock options. |
| 10/24/2024 | Date of stock options grant with exercise price $61.51, expiring 10/26/2033. |
| 10/24/2024 | Date of stock options grant with exercise price $68.37, expiring 10/24/2034. |
| 10/28/2024 | Date of filing of the Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.